PMID- 29875415
OWN - NLM
STAT- MEDLINE
DCOM- 20191011
LR  - 20220410
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 8
IP  - 1
DP  - 2018 Jun 6
TI  - The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its 
      induced adverse events: a systematic review and meta-analysis.
PG  - 8666
LID - 10.1038/s41598-018-26811-9 [doi]
LID - 8666
AB  - FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, 
      even though it induces significant adverse effects. Several institutions have 
      begun using modified FOLFIRINOX to decrease its side effects and increase its 
      tolerability. We systematically investigated the outcome from patients who 
      initially received modified FOLFIRINOX as a chemotherapy regimen for advanced 
      pancreatic cancer. We used the random-model generic inverse variance method to 
      analyse the binary data with 95% confidence intervals (CIs). Eleven studies were 
      included in the meta-analysis with 563 total patients. The 6-month and 1-year 
      overall survival (OS) rates of locally advanced pancreatic cancer (LAPC) were 
      90.9% and 76.2%. The 6-month and 1-year progression-free survival (PFS) rates of 
      LAPC were 81.5% and 48.5%. The 6-month and 1-year OS rates of metastatic 
      pancreatic cancer (MPC) were 79.7% and 47.6%. The 6-month and 1-year PFS rates of 
      MPC were 56.3% and 20.6%. The following rates were also calculated: complete 
      response rate (CR): 2.9%; partial response rate (PR): 35.9%; stable disease rate 
      (SD): 41.2%; overall response rate (OR): 34.6%; disease control rate (DCR): 
      76.7%; progressive disease: 23.1%; and grade III/IV adverse events (AEs): 
      neutropenia 23.1%, febrile neutropenia 4.8%, thrombocytopenia 4.8%, anaemia 5.7%, 
      fatigue 11.5%, nausea 9.1%, diarrhoea 10.1%, vomiting 5.7%, neuropathy 3.8%, and 
      increased ALT 5.7%. In conclusion, modified FOLFIRINOX could provide comparative 
      survival benefits with fewer adverse events compared to the conventional dosage.
FAU - Tong, Hongxuan
AU  - Tong H
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 10029, 
      China.
FAU - Fan, Zhu
AU  - Fan Z
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 10029, 
      China.
FAU - Liu, Biyuan
AU  - Liu B
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 10029, 
      China.
FAU - Lu, Tao
AU  - Lu T
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 10029, 
      China. taolu@bucm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180606
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antineoplastic Agents)
RN  - 0 (folfirinox)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - Fatigue/chemically induced
MH  - Fluorouracil/adverse effects/therapeutic use
MH  - Humans
MH  - Irinotecan/adverse effects/therapeutic use
MH  - Leucovorin/adverse effects/therapeutic use
MH  - Nausea/chemically induced
MH  - Neutropenia/chemically induced
MH  - Oxaliplatin/adverse effects/therapeutic use
MH  - Pancreas/drug effects/pathology
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Survival Analysis
MH  - Thrombocytopenia/chemically induced
MH  - Treatment Outcome
PMC - PMC5989209
COIS- The authors declare no competing interests.
EDAT- 2018/06/08 06:00
MHDA- 2019/10/12 06:00
PMCR- 2018/06/06
CRDT- 2018/06/08 06:00
PHST- 2017/09/29 00:00 [received]
PHST- 2018/05/11 00:00 [accepted]
PHST- 2018/06/08 06:00 [entrez]
PHST- 2018/06/08 06:00 [pubmed]
PHST- 2019/10/12 06:00 [medline]
PHST- 2018/06/06 00:00 [pmc-release]
AID - 10.1038/s41598-018-26811-9 [pii]
AID - 26811 [pii]
AID - 10.1038/s41598-018-26811-9 [doi]
PST - epublish
SO  - Sci Rep. 2018 Jun 6;8(1):8666. doi: 10.1038/s41598-018-26811-9.